#### **Company Overview** Bajaj Healthcare Limited (BHL) is a prominent, vertically integrated Indian pharmaceutical company established in 1993 and headquartered in Thane, Maharashtra. Over the past three decades, BHL has evolved from a bulk manufacturer into a specialty pharmaceutical player with a diversified portfolio across **Active Pharmaceutical Ingredients (APIs), Intermediates, Finished Dosage Formulations (FDFs), and Nutraceuticals**. With 15 state-of-the-art manufacturing facilities across India—primarily in Tarapur (Maharashtra), Vadodara, Ankleshwar, and Dahej (Gujarat)—the company serves over **60 countries** globally, including regulated markets in the USA, Europe, Australia, South America, and the Middle East. --- #### **Business Segments & Revenue Streams** BHL operates in four key revenue-generating segments: 1. **Domestic APIs** 2. **Exported APIs** 3. **Formulations (FDFs)** 4. **Opium & Alkaloid Processing** - **APIs contribute over 83% of total revenue**, forming the core of BHL’s business. - **Exports account for more than 24% of total revenue**, with strong YoY growth in H1 FY26 at **67.7%** for exported APIs, reflecting expanding global demand. - The **Formulations segment** has shown accelerated growth—rising **68.9% YoY in FY25** and contributing **~17% of total revenue**—driven by new product launches and increased capacity utilization. - The **Opium Processing segment**, a high-margin niche, has emerged as a major growth engine, registering a **582.9% YoY surge in Q2 FY25** and contributing **10.3% of total revenue**. --- #### **Manufacturing & Capacity** BHL has one of the most robust manufacturing footprints in the Indian pharmaceutical sector: - **API & Intermediate Capacity**: **824 MT/month** - Ascorbic Acid: 120 MT/month (India’s largest producer) - Theobromine: 25 MT/month - Chlorhexidine (CH) Base: **World’s largest manufacturer** - **Finished Dosage Formulations (FDFs)**: **100 million units/month** (up from 92 million in 2022) - **Intermediates**: Annual capacity of **94 metric tons**, including specialty intermediates like: - **Calcium Phosphoryl Choline Chloride (CPCC)** - **Chlorhexidine (CH) Base** - Fully captive consumption supports internal API and FDF value chain The company's **FDF facility in Vadodara, Gujarat**, is compliant with **USFDA, EU-GMP, TGA (Australia), and MHRA (UK)** standards, enabling access to highly regulated markets. --- #### **Regulatory Excellence & Global Reach** BHL is distinguished by its **strong regulatory credentials**: - Facilities accredited by **US FDA, EU-GMP, WHO-GMP, KFDA (South Korea), TGA, MHRA, ISO 9001:2015, FSSC 22000, and HACCP**. - **575 Drug Master Files (DMFs)** filed globally, including with the **USFDA, UK MHRA, and EDQM**. - **3 new CEP approvals and 1 ASMF approval** received from European regulators in FY25. - Recognized as the **first private firm in India authorized by the Government of India** to process **opium gum and poppy straw** under two exclusive contracts—marking a strategic entry into the high-margin **alkaloid processing** space. --- #### **Research & Development (R&D)** BHL has transformed into an **R&D-driven organization**, pivoting from a volume-based to a **value-driven growth model**: - R&D center in **Vadodara** is **DSIR-recognized** and equipped with advanced instrumentation for synthetic chemistry, process research, and scale-up. - Focus areas include: - **Reverse engineering of off-patent APIs** - **Development of complex generics and CNS drugs** - **Environmentally friendly, non-infringing synthesis routes** - Over **6–10 new molecules launched annually**, including **Posaconazole (for Mucormycosis)**, **Favipiravir**, and **Ivermectin** during the pandemic. - Strong IP creation capability: **Dr. Mohammed Jaweed Mukarram**, a key R&D executive, has filed **156 patent applications** and managed over 70 bulk drugs. --- #### **Clinical & Pipeline Advancements (CNS Focus)** Bajaj Healthcare has made significant strides in the **central nervous system (CNS)** therapeutic area: | Drug | Status | |------|--------| | **Suvorexant Tablets** (for insomnia) | **Received SEC-CDSCO clearance for Phase III trials** – **first Indian company** to do so | | **Cenobamate Tablets** (anti-epileptic) | **DCGI approval secured for Phase III trials** | | **Pimavanserin** (for Parkinson's disease psychosis) | **DCGI approval received (March 2025)**; launched in India in partnership; potential global sales >$1 billion | | **Magnesium L-Threonate (Magtein®)** | Validation batches in progress; **planned commercial launch in Q3 FY26** | The company is positioning itself as a **leader in complex CNS generics**, leveraging its integrated manufacturing and regulatory expertise. --- #### **Strategic Growth Drivers** 1. **Vertical Integration** - Strong **backward integration** in intermediates supports cost efficiency. - **Captive consumption** of ~100 APIs and intermediates enhances supply chain resilience and margin protection. - Reducing dependence on Chinese APIs through in-house production. 2. **Forward Integration into CDMO & FDFs** - Entered FDF business in **2008**; now accounts for **~17% of revenue**. - Secured **CDMO contracts for 30+ APIs** with UK and EU partners. - Focus on **complex generics and niche molecules** in regulated markets. 3. **Strategic Acquisitions** - **Acquired Genrx Pharmaceuticals Pvt. Ltd. (April 2025)**, enhancing in-house capacity for **allopathic, nutraceutical, and natural formulations**. - Previous acquisitions under SARFAESI Act added **111 MT/month API capacity** and expanded product portfolio (e.g., Artemether, Lumefantrine, Nimesulide). - **Dahej greenfield project** planned to further expand scale and capabilities. 4. **Expansion in High-Margin Segments** - **Alkaloid Processing Plant** in Savli, Gujarat: - Capacity: **250 MT opium gum / 2,500 MT poppy straw per annum** - Revenue from this segment grew **283% in FY24** - Expected to become a **major EBITDA contributor** due to high margins and government demand 5. **Global Expansion** - Exports to **60+ countries**, with key markets in **USA, UK, Germany, Japan, Brazil, China, Australia, and South Africa**. - Expanding presence in **semi-regulated markets** via upgraded FDF facilities. - Dedicated **in-house product registration team** supports rapid international approvals. --- #### **Financial & Operational Highlights** - **Revenue Growth**: - **Formulations revenue grew 68.9% YoY to ₹915.6 million in FY25** - **Exported API revenue grew 8.6% YoY to ₹1,241.4 million** - **Workforce**: Over **1,500 employees** with strong leadership including: - **Mr. Sajankumar R. Bajaj**: Chairman & Managing Director (30+ years in pharma) - **Mr. Rohan Parekh**: CFO (appointed May 2025; ex-Home First Finance) - **Mr. Amit Rajan**: Technical & Regulatory Advisor (22+ years in global regulatory affairs) - **R&D Investment**: Increasing focus on **asymmetric APIs, CNS drugs, and off-patent molecules** with future pipeline aligned to patent expiries. --- #### **Competitive Advantages** 1. **Vertically Integrated Model** – From raw materials to finished products. 2. **Regulatory Leadership** – Multiple USFDA, EU-GMP, TGA, MHRA, and EDQM approvals. 3. **Scale & Cost Efficiency** – Economies of scale in API and intermediate production. 4. **Proprietary Intermediate Manufacturing** – One of the world’s few CH Base and CPCC producers. 5. **CNS Specialization** – Emerging leader in a high-barrier, high-growth therapeutic area. 6. **Government-Backed Opium Processing** – Exclusive and sustainable revenue stream. --- #### **Recent Milestones (2024–2025)** | Date | Key Development | |------|-----------------| | **Oct 2025** | SEC-CDSCO clearance for Phase III trials of **Suvorexant** and DCGI approval for **Cenobamate** | | **May 2025** | **Acquisition of Genrx Pharmaceuticals**; commercial launch of **Pimavanserin** in India | | **Feb 2025** | TGA (Australia) approval for Gujarat API site; DCGI greenlight for **Pimavanserin** manufacture | | **Nov 2024** | Opium Processing revenue surged **582.9% YoY**; signed development deal with European API partner | | **Jul 2025** | Export revenue share increased to **35%**, up from 23% previously | | **FY25** | Filed **575 DMFs**, launched **Magtein®**, and secured **6 CEPs** for EU commercialization |